Skip to content
DraconiticResearch
Search Sources API
210,049 studies31 sourcesUpdated 59 min ago

Oncology

5,302 studies557 in 7 days2,546 in 30 days

Filters
Type
Date
Clear

Latest

5,302 studies

  1. Chinese medicine combined with EGFR-TKIs in EGFR-mutated advanced NSCLC: a meta-analysis of efficacy and safety
    Xiaohong Li, Die Qian, Shuai Liu +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyPMCCrossrefEurope PMC
  2. Global and registry-based patterns of pancreatic cancer: GLOBOCAN 2020, CI5plus trends (2000–2017), and demographic projections to 2040
    Xin Jin, Xiao Guan, Yongrun Mu +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyPMCCrossrefEurope PMC
  3. Experiences and perspectives of Ayurvedic practitioners on non-communicable disease management in the UK: A qualitative study
    Patricia Egwumba, Manpreet Bains, Laura Nellums +1
    PLOS OnePeer-reviewedCC BY 4.0Full textOncologySurgery & anaesthesiaPLOS
  4. ReViT-RF: A hybrid ResNet-50–Vision Transformer with a Radiomic Feature Fusion framework for lung tumor classification and TNM-based stage prediction using CT images
    Shobharani DA, Ramesh Naik B
    PLOS OnePeer-reviewedCC BY 4.0Full textMedical imaging & radiologyOncologyPLOS
  5. An interpretable machine-learning signature predicts early triple-negative breast cancer recurrence but adds no prognostic value beyond clinicopathological factors in external validation
    Haocheng Nan, Rong Di, Xiaorong Kou +1
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  6. Clinical significance of intramammary lymph nodes in female primary breast cancer: a systematic review and meta-analysis
    Zijun Zhao, Xiangyu Wang, Wenxiang Zhang +9
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  7. IκBζ target genes in chronic lymphocytic leukemia
    Ilenia Sana, Miriam Meloni, Francesca Genova +12
    iSciencePeer-reviewedCC BY-NC 4.0Full textOncologyCell PressCrossrefEurope PMC
  8. Quantitative systems pharmacology modeling of class I–III BRAF-mutant NSCLC enables subgroup treatment analysis and combination therapy design
    Jingjing Hu, Qi Rao, Zichun Li +5
    iSciencePeer-reviewedCC BY 4.0Full textOncologyPharmacology & toxicologyCell PressCrossrefEurope PMC
  9. Prostate Cancer Patient‐Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)‐Based Personalized Therapy
    Thi Thom Tran, Thi Tu Uyen Phan, Michael Baboudjian +13
    Advanced Healthcare MaterialsPeer-reviewedCC BY 4.0Full textOncologyPMC
  10. CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma
    C. Custodia, R. Cascao, E. Paisana +12
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  11. PIEZO1 marks a low neuroendocrine state and supports cisplatin tolerance in small cell lung cancer
    Z. Wang, L. Zeng, X. Sun +3
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  12. Cyclic Hypoxia drives Wnt5a-ROR1 stroma-tumor crosstalk promoting breast cancer growth
    Yamin Liu, Shaofei Liu, Sarthak Sarhoo +7
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxivPMC
  13. FLASH X-rays preserve neutrophil chromatin to boost antitumor immunity
    X. Shi, S. Qiu, Y. Yang +38
    bioRxivPreprintCC BYFull textOncologybioRxiv
  14. Cross-Platform External Validation of a Locked 12-Gene Prognostic Panel in Lung Adenocarcinoma Benchmarked Against Pathological Stage.
    Faris Alrumaihi
    GenesPeer-reviewedCC BYFull textOncologyEurope PMC
  15. Synergistic psychosocial pathways linking resilience to self-efficacy in lung cancer following video-assisted thoracic surgery: a cross-sectional study.
    Xinru Chen, Gaoyang Duan, Jiudi Zhong +3
    International journal of nursing studies advancesPeer-reviewedCC BYFull textOncologyEurope PMC
  16. Beyond ERBB2 amplification: RNA and proteomic HER2 assessment for pan-tumor treatment stratification
    K. Egebjerg, K. S. Rohrberg, F. O. Bagger +24
    medRxivPreprintCC BYFull textOncologymedRxiv
  17. The value of breast brachytherapy boost in the current era: a narrative literature review from the GEC-ESTRO breast cancer working group.
    Irene Martínez Montesinos, Katarzyna Konat-Bąska, José-Luis Guinot +5
    Clinical and translational radiation oncologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  18. Baseline circulating immunophenotype as a predictor of immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors
    A. Dodi, G. Mazzaschi, F. Pecci +17
    ImmunotherapyPeer-reviewedLicence not statedFull textOncologyPMC
  19. SPP1-CD44-Mediated Crosstalk Between Endothelial and Macrophage Subpopulations Promotes Pancreatic Ductal Adenocarcinoma Progression Through S100A6 Upregulation
    Yanbin Zhou, Sixian Guo, Wenhu Zhou +1
    CellsPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  20. Pyrazolate-Bridged PdCo and PdCu Complexes as Dual DNA-Binding and ROS-Driven Cytotoxic Agents
    Marina A Uvarova, Vitalia V Kulikova, Yaroslav V Kozmenko +8
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  21. Lipid-Phase Access Does Not Explain P-Glycoprotein Substrate Selection in Matched Pairs
    Hayat Ullah, Khwaja Jawad, Khan Ziaullah +3
    ChemRxivPreprintCC BYFull textOncologyChemRxiv
  22. Efficacy and safety of anlotinib in bevacizumab-pretreated patients with non-squamous non-small cell lung cancer (AN-BELIEF study): a multicenter retrospective study.
    Jiale Wang, Xinxin Zhi, Jinzhang Chen +10
    Translational lung cancer researchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCPMC
  23. The miR-744-5p/connexin 43 axis modulates Salmonella-containing vacuole association with the Golgi network
    Jane Dias, Caio Haddad Franco, Laura Maria Alcantara +3
    The EMBO JournalPeer-reviewedCC BY 4.0Full textOncologyPMC
  24. Synthesis, Cytotoxicity, and Mechanistic Evaluation of Thiazolium-Based Gold(I) Bis‑N‑Heterocyclic Carbene Complexes
    Melanie E. Hoffmann, Lisa C. Haas, Fernanda Marques +6
    Inorganic ChemistryPeer-reviewedCC BY 4.0Full textOncologyPMC
  25. TPX2 promotes osteosarcoma progression by conferring ferroptosis resistance through the AURKA/NRF2 signaling axis
    Huashun Liu, Lan Tang, Biao Chen +1
    Journal of Bone OncologyPeer-reviewedCC BY-NC-ND 4.0Full textOncologyDOAJPMC